Medios AG (ILM1) - Total Liabilities
Based on the latest financial reports, Medios AG (ILM1) has total liabilities worth €398.53 Million EUR (≈ $465.92 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medios AG - Total Liabilities Trend (2009–2025)
This chart illustrates how Medios AG's total liabilities have evolved over time, based on quarterly financial data. See ILM1 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Medios AG Competitors by Total Liabilities
The table below lists competitors of Medios AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BMTC Group Inc
TO:GBT
|
Canada | CA$169.25 Million |
|
Vodafone Group PLC
LSE:VOD
|
UK | GBX75.52 Billion |
|
Shenzhen Sine Electric Co. Ltd. A
SHG:688395
|
China | CN¥164.89 Million |
|
Precious Shipping Public Company Limited
BK:PSL-R
|
Thailand | ฿9.21 Billion |
|
D-Link Corp
TW:2332
|
Taiwan | NT$5.07 Billion |
|
Omega Flex Inc
NASDAQ:OFLX
|
USA | $18.69 Million |
|
Reconnaissance Energy Africa Ltd
V:RECO
|
Canada | CA$4.67 Million |
|
Corem Property Group AB (publ)
ST:CORE-PREF
|
Sweden | Skr38.77 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Medios AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ILM1 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medios AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medios AG (2009–2025)
The table below shows the annual total liabilities of Medios AG from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €388.82 Million ≈ $454.57 Million |
-8.33% |
| 2024-12-31 | €424.17 Million ≈ $495.89 Million |
+236.78% |
| 2023-12-31 | €125.95 Million ≈ $147.24 Million |
-1.54% |
| 2022-12-31 | €127.91 Million ≈ $149.54 Million |
-1.59% |
| 2021-12-31 | €129.98 Million ≈ $151.96 Million |
+149.42% |
| 2020-12-31 | €52.11 Million ≈ $60.92 Million |
+49.14% |
| 2019-12-31 | €34.94 Million ≈ $40.85 Million |
+25.15% |
| 2018-12-31 | €27.92 Million ≈ $32.64 Million |
+74.17% |
| 2017-12-31 | €16.03 Million ≈ $18.74 Million |
+16.48% |
| 2016-12-31 | €13.76 Million ≈ $16.09 Million |
+7321.68% |
| 2015-12-31 | €185.43K ≈ $216.79K |
+106.53% |
| 2014-12-31 | €89.78K ≈ $104.97K |
-60.37% |
| 2013-12-31 | €226.54K ≈ $264.85K |
-15.52% |
| 2012-12-31 | €268.14K ≈ $313.49K |
-4.48% |
| 2011-12-31 | €280.72K ≈ $328.20K |
-45.84% |
| 2010-12-31 | €518.32K ≈ $605.98K |
-117.75% |
| 2009-12-31 | €-2.92 Million ≈ $-3.41 Million |
-- |
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and p… Read more